. 2014 Aug 27;211(4):508–517. doi: 10.1093/infdis/jiu444

Table 3.

Functional Immunoglobulin G Responses in Human Immunodeficiency Virus Type 1–Exposed Vaccinated Infants

Variable	PACTG 230					PACTG 326
Variable	Placebo	VaxGen Vaccine	P Value	Chiron Vaccine	P Value	Placebo	ALVAC/ AIDSVAX	P Value
ADCC (B. SF162)
Week 24
Subjects, no.	14	40		36		9	6
Median ADCC titer	70	ND		49	.06^a	49	61	.95^a
Detectable response, subjects, %	64	ND		36	.11^b	44	67	.61^b
Week 52
Subjects, no.	12	40		43		11	6
Median ADCC titer	49	49	.8^a	49	.8^a	49	52	.07^a
Detectable response, subjects, %	17	15	1.00^b	23	1.00	9	50	.10^b
Neutralization (B. MN)
Week 24
Subjects, no.	14	40		37		9	8
Median ID₅₀^c	141	110	.8^a	187.5	.49^a	76.5	105	.86^a
Response, subjects, %	36	80	.006^b	72	.03^b	67	63	1.00
Week 52
Subjects, no.	11	40		43		11	6
Median ID₅₀^c	23	33	.22^a	68	.02^a	ND	ND
Response, subjects, %	45	50	1.00	53	.74^b	9	17

A P value of < .05 is considered statistically significant.

Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; B. MN, B HIV-1 MN.3; B. SF162, B HIV-1 SF162.LS; ID₅₀, median infectious dose; ND, not done; PACTG, Pediatric AIDS Clinical Trials Group.

By the Wilcoxon test, compared with placebo.

By the Fisher exact test, compared with placebo.

The median value was computed for responders only.